In a recent study published in the journal Scientific Reports, researchers showed that a new test developed by a team of researchers at the UBC allows clinicians to quantity the effects of gene silencing therapy for patients with Huntington’s disease (HD) and will support the first…
News
A groundbreaking research initiative on cell reprogramming for drug development against Huntington’s disease recently received $1.19 million worth of funding for the next 3 years, thanks to the Health Research Council to University of Auckland. Lead investigator and neuroscientist, Associate Professor Bronwen Connor, will attempt to better understand the disease, particularly…
A multi-institutional team with researchers from the Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium recently published in the journal Cell a new breakthrough in Huntington’s disease by identifying new genetic variants that can accelerate or delay symptom onset in patients. The study is entitled “…
In a new study entitled “Allosteric interactions between agonists and antagonists within the adenosine A2A receptor-dopamine D2 receptor heterotetramer” researchers determined the structure of a key receptor underlying neurodegenerative diseases, including Parkinson’s disease, and showed how current drugs targeting these receptors and used to treat Parkinson’s can…
In a new study entitled “Low-Dose Irradiation Enhances Gene Targeting in Human Pluripotent Stem Cells” researchers showed that providing low-dose radiation to human pluripotent stem cells can enhance gene-editing, allowing a faster and less expensive throughput of edited cells to understand and find the cure for several diseases…
Isis Pharmaceuticals, Inc. a leading company in RNA-targeted drug discovery and development, recently announced they will initiate a new Phase I/IIa clinical trial of ISIS_HTTRx for the treatment of Huntington’s disease (HD). Roche will give Isis a milestone payment of $22 million for the initiation of the trial. The placebo-controlled,…
Fingolimod, a drug often prescribed to patients with Multiple Sclerosis (MS), has found a new application to treat patients with cognitive impairment in Huntington’s Disease. These were the conclusions of a group of researchers at the University of Barcelona (UB) and the August Pi i Sunyer Biomedical Research Institute (IDIBAPS), who studied…
The Huntington’s Disease Society of America has selected Dr. Neil Aronin, a professor of medicine, to be this year’s recipient of its prestigious Research Award in recognition of his transformative contributions to what is now known about Huntington’s disease, a rare, inherited neurodegenerative condition. Dr. Aronin is currently the chief of…
Researchers from the Scripps Research Institute identified the protein Rhes as a crucial player in neuronal death in the striatum, the brain region responsible for motor and cognitive functions. The study entitled “Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington’s…
A new study recently published in the journal Molecular Psychiatry revealed a new cellular property distinctive of Huntington’s disease pathogenesis. The study is entitled “Huntington’s disease cerebrospinal fluid seeds aggregation of mutant huntingtin” and was conducted by researchers at the University of California-Irvine,…
Recent Posts
- What the holidays mean when living with Huntington’s disease
- $12M grant will back first trial of stem cell therapy for Huntington’s
- A tribute to the kindness of strangers in life with Huntington’s
- How to support someone who is planning for future care
- Antipsychotics improve functional capacity, independence in HD
- Despite dwindling resources, hope endures among researchers
- The ‘invisible’ symptoms of Huntington’s that people don’t see
- Genetic variant delays Huntington’s onset by up to 23 years: Study
- Watching Huntington’s switch roles in our marriage was jarring
- The gift of community is what I’m most thankful for this year